^{Source: France 24}

President Donald Trump's proposed tariffs on imported pharmaceuticals are raising alarms across the healthcare industry. Experts caution that these measures could significantly increase drug prices, exacerbate existing shortages, and disrupt the intricate global supply chains that the U.S. pharmaceutical industry relies upon.​

Tariffs Targeting Pharmaceuticals: A Double-Edged Sword​

In a recent announcement, President Trump indicated plans to impose substantial tariffs on imported pharmaceuticals, aiming to bolster domestic manufacturing. While the intention is to encourage drugmakers to relocate production to the U.S., industry analysts warn that the immediate impact could be detrimental to both manufacturers and patients.

The proposed tariffs include a 25% levy on imports from Canada and Mexico and a 10% charge on goods from China. Given that a significant portion of active pharmaceutical ingredients (APIs) and finished drugs are sourced from these countries, the tariffs could disrupt the supply chain and lead to increased production costs. ​

Generic Drug Manufacturers at Risk​

Generic drugs, which constitute approximately 90% of prescriptions filled in the U.S., are particularly vulnerable. These medications often have slim profit margins and rely heavily on imported APIs. The Association for Accessible Medicines (AAM) has expressed concern that the added financial burden from tariffs could force some generic manufacturers to exit the market, reducing competition and leading to higher prices for consumers. ​

Furthermore, the Healthcare Distribution Alliance notes that distributors operate on profit margins as low as 0.3%. The increased costs from tariffs could strain these businesses, potentially leading to supply chain disruptions and further exacerbating drug shortages.

Potential Impact on Drug Shortages​

The U.S. is already grappling with significant drug shortages, with over 270 active shortages reported. Experts warn that tariffs could worsen this situation, particularly for sterile injectable generics used in hospitals, such as chemotherapy drugs and IV saline. These products are complex to manufacture and have low profit margins, making them especially susceptible to supply disruptions.​

Marta Wosińska, a senior fellow at the Brookings Institution, highlights that manufacturers of these injectables may not be able to absorb the increased costs or pass them on due to fixed-price contracts with group purchasing organizations. This could lead to manufacturers exiting the market or compromising on quality, both of which would negatively impact patient care.​

Branded Drugs: Higher Costs for Consumers​

While branded drugs are often produced domestically, a significant portion is still imported, particularly from Europe. Tariffs on these imports could lead to higher prices for consumers, especially those with high-deductible insurance plans or high coinsurance rates.​

Mariana Socal from Johns Hopkins Bloomberg School of Public Health notes that manufacturers of branded drugs, protected by patents, may pass the increased costs onto consumers without fear of competition. This could further strain the affordability of prescription medications in the U.S., where drug prices are already two to three times higher than in other developed countries.​

Industry Response: Investments in U.S. Manufacturing​

In response to the looming tariffs, several pharmaceutical companies have announced significant investments in U.S. manufacturing. Novartis plans to invest $23 billion over the next five years to build and expand ten facilities, including six new manufacturing plants and a research and development center in San Diego. This initiative aims to create over 4,000 jobs and reduce reliance on foreign imports.

Similarly, Eli Lilly and Johnson & Johnson have announced multi-billion-dollar expansions of their U.S. operations. However, industry experts caution that establishing new production facilities can take up to a decade and cost as much as $2 billion, making it a long-term solution rather than an immediate fix.​‍

Navigating the Complexities of Pharmaceutical Tariffs​

While the goal of bolstering domestic pharmaceutical manufacturing is commendable, the proposed tariffs could have unintended consequences that may outweigh the benefits. Increased drug prices, exacerbated shortages, and strained supply chains could negatively impact patient care and the broader healthcare system.​

Policymakers must carefully consider these factors and collaborate with industry stakeholders to develop strategies that enhance domestic production without compromising access to affordable medications.

‍